Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure
- PMID: 16391172
- DOI: 10.1161/01.HYP.0000199982.71858.11
Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure
Abstract
Patients with autonomic failure are disabled by orthostatic hypotension, which can be worsened by the nighttime pressure natriuresis induced by associated supine hypertension. Several pharmacological agents are available that effectively reduce nighttime hypertension, but none of them prevent pressure natriuresis. Because hypertension of autonomic failure can be driven by residual sympathetic tone, we hypothesized that clonidine would be effective in reducing blood pressure (BP) and nocturnal natriuresis. Therefore, we determined the effect of placebo, 0.1 mg clonidine, and 0.1-mg/h nitroglycerin transdermal patch on supine BP, orthostatic hypotension, and pressure natriuresis in 23 patients with primary autonomic failure and supine hypertension. Medications were given at 8:00 PM, and BP was recorded every 2 hours for 12 hours. The maximal decrease in BP was seen 6 to 8 hours after drug administration and was similar to clonidine and nitroglycerin (-29+/-9 and -30+/-10 mm Hg, respectively), as was the average fall in BP throughout the night. However, only clonidine effectively reduced nocturnal natriuresis (-0.09 mmol/mg Cr; 95% CI, -0.13 to -0.04; P=0.004), but this was not associated with improvement in morning orthostatic hypotension because of a residual hypotensive effect. The decrease in BP induced by clonidine was modestly but significantly correlated with the magnitude of residual sympathetic tone determined in 10 subjects by the fall in BP induced by ganglionic blockade (r=0.66; P=0.043). These results are consistent with residual sympathetic tone contributing to supine hypertension in autonomic failure, which can be targeted with clonidine to decrease BP and nocturnal natriuresis.
Similar articles
-
Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure.J Am Soc Nephrol. 1999 Jan;10(1):35-42. doi: 10.1681/ASN.V10135. J Am Soc Nephrol. 1999. PMID: 9890307 Clinical Trial.
-
Autonomic Nervous System Dysfunction in Patients With Parkinson Disease Having Depression.J Geriatr Psychiatry Neurol. 2016 Jan;29(1):11-7. doi: 10.1177/0891988715598234. Epub 2015 Jul 30. J Geriatr Psychiatry Neurol. 2016. PMID: 26232405
-
[Orthostatic hypotension and supine hypertension in pure autonomic failure].Ital Heart J Suppl. 2004 Nov;5(11):879-83. Ital Heart J Suppl. 2004. PMID: 15633433 Italian.
-
Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.CNS Drugs. 2017 Aug;31(8):653-663. doi: 10.1007/s40263-017-0453-9. CNS Drugs. 2017. PMID: 28702747 Review.
-
Diagnostic and therapeutical management of supine hypertension in autonomic failure: a review of the literature.J Hypertens. 2019 Jun;37(6):1102-1111. doi: 10.1097/HJH.0000000000002008. J Hypertens. 2019. PMID: 30672835 Review.
Cited by
-
Current concepts in orthostatic hypotension management.Curr Hypertens Rep. 2013 Aug;15(4):304-12. doi: 10.1007/s11906-013-0362-3. Curr Hypertens Rep. 2013. PMID: 23832761 Free PMC article. Review.
-
Management of coexistent neurogenic orthostatic hypotension and supine hypertension.J Clin Hypertens (Greenwich). 2019 Nov;21(11):1732-1734. doi: 10.1111/jch.13699. Epub 2019 Oct 10. J Clin Hypertens (Greenwich). 2019. PMID: 31599484 Free PMC article. No abstract available.
-
Orthostatic Hypotension: Management of a Complex, But Common, Medical Problem.Circ Arrhythm Electrophysiol. 2022 Mar;15(3):e010573. doi: 10.1161/CIRCEP.121.010573. Epub 2022 Feb 25. Circ Arrhythm Electrophysiol. 2022. PMID: 35212554 Free PMC article. Review.
-
Pharmacotherapy of autonomic failure.Pharmacol Ther. 2012 Jun;134(3):279-86. doi: 10.1016/j.pharmthera.2011.05.009. Epub 2011 Jun 12. Pharmacol Ther. 2012. PMID: 21664375 Free PMC article. Review.
-
Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions.J Neurol. 2023 Nov;270(11):5251-5273. doi: 10.1007/s00415-023-11876-y. Epub 2023 Jul 21. J Neurol. 2023. PMID: 37477834 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical